Association of MAOA gene functional promoter polymorphism with CSF dopamine turnover and atypical depression

Pharmacogenetics and Genomics

Volumn 19, Issue 4, 2009, Pages 267-275

  Aklillu, Eleni ^a   Karlsson, Sara ^d   Zachrisson, Olof O ^b   Ozdemir, Vural ^c   Agren, Hans ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY OF MONTREAL   (Canada)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

3 methoxy 4 hydroxyphenylglycol; 5 hydroxyindoleacetic acid; Association analysis; Atypical depression; Cerebrospinal fluid; Homovanillic acid; Monoamine oxidase A; Polymorphism; Promoter; Sex influence

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; DOPAMINE; HOMOVANILLIC ACID; NORADRENALIN; SEROTONIN;

ADULT; ALLELE; ARTICLE; ATYPICAL DEPRESSION; CEREBROSPINAL FLUID LEVEL; ENZYME ACTIVITY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAOA GENE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; SEX DIFFERENCE; VARIABLE NUMBER OF TANDEM REPEAT;

CASE-CONTROL STUDIES; DEPRESSION; DOPAMINE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; HYDROXYINDOLEACETIC ACID; LOGISTIC MODELS; MALE; METHOXYHYDROXYPHENYLGLYCOL; MODELS, BIOLOGICAL; MONOAMINE OXIDASE; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; SCANDINAVIA; SEX FACTORS;

EID: 63849288990     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328328d4d3     Document Type: Article

References (53)

1. Angst J, Gamma A, Benazzi F, Silverstein B, Ajdacic-Gross V, Eich D, et al. Atypical depressive syndromes in varying definitions. Eur Arch Psychiatry Clin Neurosci 2006; 256:44-54.
2. Quitkin FM. Depression with atypical features: diagnostic validity, prevalence, and treatment. Prim Care Companion J Clin Psychiatry 2002; 4:94-99.
3. Benazzi F. Can only reversed vegetative symptoms define atypical depression? Eur Arch Psychiatry Clin Neurosci 2002; 252:288-293.
4. Kendler KS, Eaves U, Walters EE, Neale MC, Heath AC, Kessler RC. The identification and validation of distinct depressive syndromes in a populationbased sample of female twins. Arch Gen Psychiatry 1996; 53:391-399.
5. Nierenberg AA, Alpert JE, Pava J, Rosenbaum JF, Fava M. Course and treatment of atypical depression. J Clin Psychiatry 1998; 59 (Suppl 18):5-9.
6. Thase ME. Recognition and diagnosis of atypical depression. J Clin Psychiatry 2007; 68 (Suppl 8):11-16.
7. Angst J, Gamma A, Sellaro R, Zhang H, Merikangas K. Toward validation of atypical depression in the community: results of the Zurich cohort study. J Affect Disord 2002; 72:125-138.
8. Asnis GM, McGinn LK, Sanderson WC. Atypical depression: clinical aspects and noradrenergic function. Am J Psychiatry 1995; 152:31-36.
9. Sullivan PF, Prescott CA, Kendler KS. The subtypes of major depression in a twin registry. J Affect Disord 2002; 68:273-284.
10. Stewart JW, McGrath PJ, Rabkin JG, Quitkin FM. Atypical depression. A valid clinical entity? Psychiatr Clin North Am 1993; 16:479-495.
11. Shih JC, Chen K, Ridd MJ. Monoamine oxidase: from genes to behavior. Annu Rev Neurosci 1999; 22:197-217.
12. Shih JC, Chen K, Ridd MJ. Role of MAO A and B in neurotransmitter metabolism and behavior. Pol J Pharmacol 1999; 51:25-29.
13. Ozelius L, Hsu YP, Bruns G, Powell JF, Chen S, Weyler W, et al. Human monoamine oxidase gene (MAOA): chromosome position (xp21-p11) and DNA polymorphism. Genomics 1988; 3:53-58.
14. Sabol SZ, Hu S, Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet 1998; 103:273-279.
15. Deckert J, Catalano M, Syagailo YV, Bosi M, Okladnova O, Di Bella D, et al. Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. Hum Mol Genet 1999; 8:621-624.
16. Endicott J, Spitzer RL. Schedule for Affective Disorders and Schizophrenia (SADS). Acta Psychiatr Belg 1987; 87:361-516.
17. Endicott J. Diagnostic interview schedule: reliability and validity. Arch Gen Psychiatry 1981; 38:1300-1301.
18. Spitzer RL, Williams JB, Gibbon M, First MB. The structured clinical interview for DSM-III-R (SCID). I: History, rationale, and description. Arch Gen Psychiatry 1992; 49:624-629.
19. Ekselius L, Lindström E, Von Knorring L, Bodlund O, Kullgren G. SCID II interviews and the SCID Screen questionnaire as diagnostic tools for personality disorders in DSM-III-R. Acta Psychiatr Scand 1994; 90:120-123.
20. Heilig M, Zachrisson O, Thorsell A, Ehnvall A, Mottagui-Tabar S, Sjogren M, et al. Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. J Psychiatr Res 2004; 38b:113-121.
21. Blennow K, Wallin A, Gottfries CG, Karlsson I, Mansson JE, Skoog I, et al. Cerebrospinal fluid monoamine metabolites in 114 healthy individuals 18-88 years of age. Eur Neuropsychopharmacol 1993; 3:55-61.
22. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986; 51:1173-1182.
23. Agren H, Mefford IN, Rudorfer MV, Linnoila M, Potter WZ. Interacting neurotransmitter systems. A non-experimental approach to the 5HIAA-HVA correlation in human CSF. J Psychiatr Res 1986; 20:175-193.
24. Benazzi F. Prevalence and clinical features of atypical depression in depressed outpatients: a 467-case study. Psychiatry Res 1999; 86:259-265.
25. Matza LS, Revicki DA, Davidson JR, Stewart JW. Depression with atypical features in the national comorbidity survey: classification, description, and consequences. Arch Gen Psychiatry 2003; 60:817-826.
26. Bierut U, Heath AC, Bucholz KK, Dinwiddie SH, Madden PA, Statham DJ, et al. Major depressive disorder in a community-based twin sample: are there different genetic and environmental contributions for men and women? Arch Gen Psychiatry 1999; 56:557-563.
27. Kendler KS, Gardner CO, Neale MC, Prescott CA. Genetic risk factors for major depression in men and women: similar or different heritabilities and same or partly distinct genes? Psychol Med 2001; 31:605-616.
28. Luine VN, Khylchevskaya Rl, McEwen BS. Effect of gonadal steroids on activities of monoamine oxidase and choline acetylase in rat brain. Brain Res 1975; 86:293-306.
29. Ho LW, Furlong RA, Rubinsztein JS, Walsh C, Paykel ES, Rubinsztein DC. Genetic associations with clinical characteristics in bipolar affective disorder and recurrent unipolar depressive disorder. Am J Med Genet 2000; 96:36-42.
30. Schulze TG, Muller DJ, Krauss H, Scherk H, Ohlraun S, Syagailo YV, et al. Association between a functional polymorphism in the monoamine oxidase A gene promoter and major depressive disorder. Am J Med Genet 2000; 96:801-803.
31. Yu YW, Tsai SJ, Hong CJ, Chen TJ, Chen MC, Yang CW. Association study of a monoamine oxidase A gene promoter polymorphism with major depressive disorder and antidepressant response. Neuropsychopharmacology 2005; 30:1719-1723.
32. Huang YY, Cate SP, Battistuzzi C, Oquendo MA, Brent D, Mann JJ. An association between a functional polymorphism in the monoamine oxidase A gene promoter, impulsive traits and early abuse experiences. Neuropsychopharmacology 2004; 29:1498-1505.
33. Manuck SB, Flory JD, Ferrell RE, Mann JJ, Muldoon MR A regulatory polymorphism of the monoamine oxidase-A gene may be associated with variability in aggression, impulsivity, and central nervous system serotonergic responsivity. Psychiatry Res 2000; 95:9-23.
34. Jonsson EG, Norton N, Gustavsson JP, Oreland L, Owen MJ, Sedvall GC. A promoter polymorphism in the monoamine oxidase A gene and its relationships to monoamine metabolite concentrations in CSF of healthy volunteers. J Psychiatr Res 2000; 34:239-244.
35. Zalsman G, Huang YY, Harkavy-Friedman JM, Oquendo MA, Ellis SP, Mann JJ. Relationship of MAO-A promoter (u-VNTR) and COMT (V158M) gene polymorphisms to CSF monoamine metabolites levels in a psychiatric sample of Caucasians: a preliminary report. Am J Med Genet B Neuropsychiatr Genet 2005; 132:100-103.
36. Ducci F, Newman TK, Funt S, Brown GL, Virkkunen M, Goldman D. A functional polymorphism in the MAOA gene promoter (MAOA-LPR) predicts central dopamine function and body mass index. Mol Psychiatry 2006; 11:858-866.
37. Williams RB, Marchuk DA, Gadde KM, Barefoot JC, Grichnik K, Helms MJ, et al. Serotonin-related gene polymorphisms and central nervous system serotonin function. Neuropsychopharmacology 2003; 28:533-541.
38. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274:1527-1531.
39. Hanna GL, Himle JA, Curtis GC, Koram DQ, Veenstra-VanderWeele J, Leventhal BL, et al. Serotonin transporter and seasonal variation in blood serotonin in families with obsessive-compulsive disorder. Neuropsychopharmacology 1998; 18:102-111.
40. Parsey RV, Hastings RS, Oquendo MA, Hu X, Goldman D, Huang YY, et al. Effect of a triallelic functional polymorphism of the serotonin-transporterlinked promoter region on expression of serotonin transporter in the human brain. Am J Psychiatry 2006; 163:48-51.
41. Shioe K, Ichimiya T, Suhara T, Takano A, Sudo Y, Yasuno F, et al. No association between genotype of the promoter region of serotonin transporter gene and serotonin transporter binding in human brain measured by pet. Synapse 2003; 48:184-188.
42. Meyer JH, Ginovart N, Boovariwala A, Sagrati S, Hussey D, Garcia A, et al. Elevated monoamine oxidase A levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry 2006; 63:1209-1216.
43. Stanley M, Traskman-Bendz L, Dorovini-Zis K. Correlations between aminergic metabolites simultaneously obtained from human CSF and brain. Life Sci 1985; 37:1279-1286.
44. Gold PW, Licinio J, Wong ML, Chrousos GP. Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs. Ann N Y Acad Sci 1995; 771:716-729.
45. McGinn LK, Asnis GM, Rubinson E. Biological and clinical validation of atypical depression. Psychiatry Res 1996; 60:191-198.
46. Iversen L Neurotransmitter transporters: fruitful targets for CNS drug discovery. Mol Psychiatry 2000; 5:357-362.
47. Jimerson DC, Lesem MD, Kaye WH, Brewerton TD. Low serotonin and dopamine metabolite concentrations in cerebrospinal fluid from bulimic patients with frequent binge episodes. Arch Gen Psychiatry 1992; 49:132-138.
48. Pickering RP, Grant BF, Chou SP, Compton WM. Are overweight, obesity, and extreme obesity associated with psychopathology? Results from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry 2007; 68:998-1009.
49. Baune BT, Hohoff C, Mortensen LS, Deckert J, Arolt V, Domschke K. Serotonin transporter polymorphism (5-HTTLPR) association with melancholic depression: a female specific effect? Depress Anxiety 2007. [Epub ahead of print]
50. Willeit M, Praschak-Rieder N, Neumeister A, Zill P, Leisch F, Stastny J, et al. A polymorphism (5-HTTLPR) in the serotonin transporter promoter gene is associated with DSM-IV depression subtypes in seasonal affective disorder. Mol Psychiatry 2003; 8:942-946.
51. Kishida I, Aklillu E, Kawanishi C, Bertilsson L, Agren H. Monoamine metabolites level in CSF is related to the 5-HTT gene polymorphism in treatment-resistant depression. Neuropsychopharmacology 2007; 32:2143-2151.
52. Henkel V, Mergl R, Allgaier AK, Kohnen R, Moller HJ, Hegerl U. Treatment of depression with atypical features: a meta-analytic approach. Psychiatry Res 2006; 141:89-101.
53. Stewart JW, Thase ME. Treating DSM-IV depression with atypical features. J Clin Psychiatry 2007; 68:e10.